Kidney Transplantation With Ultralong-Term (42 Years) Survival of a 100-Year-Old Graft

Effects of immunotherapy induction on outcome and graft survival of kidney-transplanted patients with different immunological risk of rejection

“…An ultra-long-term graft survival (42-year) was achieved in a patient transplanted without immunotherapy who received a kidney from his haploidentical mother. The graft was maintained with good function without rejection episodes or nephrotoxicity using monotherapy with azathioprine [33], showing that the type of donor and recipient care and continuous therapy had great influence on this long-term graft survival. This finding opens the discussion about the need for immunotherapy for all recipients, including nonsensitized patients, and it also suggests the use of clinical strategies to minimize the doses of drugs used in triple-maintenance immunosuppressive therapy.…”

“…However, graft survival from living and deceased donors of more than 20 years was demonstrated in transplanted recipients treated with azathioprine monotherapy [31], and long-term graft survival of more than 30 years was also similar between grafts from both types of donors [32]. A recent ultra-long-term graft survival using monotherapy was demonstrated in a patient who lived 42 years with a 100-year-old graft received from a related living donor [33]. The aim of this study was to evaluate the effects of immunotherapy by rATG on graft suvival during a 9-year period in kidney-transplanted patients with different immunological profiles.…”

Identification of four novel HLA alleles: HLA‐B*27:265, ‐B*35:569, ‐DRB1*08:117 and ‐DPB1*1435:01

“…There is overwhelming evidence supporting the benefits of HLA matching in organ and tissue transplantation, which include improved graft function, longer graft and patient survival, and a reduced risk of sensitization. [1][2][3] Despite the emergence of modern immunosuppressive agents, the importance of HLA compatibility persists as a factor in optimizing transplant outcomes.…”